The science. The stories. The evidence.
Oprimaze was built around a documented physiological problem. These are the peer-reviewed studies that define it — and the real journeys of people who found a better way through it.
Four numbers that define the problem.
These figures are not Oprimaze trial data. They're published peer-reviewed outcomes that show why a two-phase approach is a biological necessity, not a preference.
Regain within 5 years
Adults who lose ≥10% body weight without ongoing structured maintenance regain the majority within five years.
Hunger hormone surge
Appetite-stimulating hormone levels remain about twice their pre-diet baseline a year after weight loss.
Discontinuation at 1 year
A majority of people on injectable therapy do not continue at one year — exposing them to the regain window with no structured alternative.
Regain post-injectable
About two-thirds of weight lost on injectable therapy returned within 12 months of stopping in a controlled clinical trial.
Real journeys. Real outcomes.
Names abbreviated. Stories shared with permission. Individual results vary.
"I'd tried two injectable therapies and stopped both because of the nausea. The spray gave me appetite support without making me feel sick."
"I'd lost the weight twice already and put it back on each time. Phase 02 felt like the first thing actually built for the after."
"Using both phases together gave me a structure for the whole journey, not just the start."
Full reference list.
- [1] Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82(1 Suppl):222S-225S.
- [2] Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604.
- [3] Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2022;327(2):138-150.
- [4] Wilding JPH, et al. Discontinuation rates and outcomes for GLP-1 receptor agonists. Diabetes Obes Metab. 2023.
- [5] Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612-1619.
- [6] Paudel KS, et al. Cannabidiol bioavailability after nasal and oral administration. Drug Deliv. 2010.